Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 2 examiners • 0 of 3 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Alteogen Inc. has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These matters are assigned to 2 distinct examiners, which means at least one examiner is handling more than one case. The portfolio is also divided between 2 distinct art units, indicating some technical variety in the pending applications.
The busiest examiner is FRONDA, CHRISTIAN L, who is responsible for 2 pending office actions. This count of 2 represents a larger portion of the 3 total pending office actions for the company than the single action handled by the other examiner. The remaining pending action is handled by the other of the 2 distinct examiners in the portfolio.
The use of 2 distinct art units suggests that the company's 3 pending office actions are categorized into different specialized areas of biotechnology. Because FRONDA, CHRISTIAN L manages 2 of these actions, this examiner's decisions have a significant impact on the company's current prosecution outcomes. Practitioners should focus on the specific requirements of the distinct art units while managing the distinct examiners involved.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 2 (67%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FRONDA, CHRISTIAN L | 2 | 82.5% | +14.3% |
| SWIFT, CANDICE LEE | 1 | 56.6% | +37.2% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18940159 | METHOD FOR PRODUCING RECOMBINANT HYALURONIDASE | FRONDA, CHRISTIAN L | — |
| 18940064 | METHOD FOR PRODUCING RECOMBINANT HYALURONIDASE | FRONDA, CHRISTIAN L | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18721629 | N-terminal and/or C-terminal Cleaved Soluble PH20 Polypeptide and Use Thereof | SWIFT, CANDICE LEE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18940159 | METHOD FOR PRODUCING RECOMBINANT HYALURONIDASE | FRONDA, CHRISTIAN L | — |
| 18940064 | METHOD FOR PRODUCING RECOMBINANT HYALURONIDASE | FRONDA, CHRISTIAN L | — |
| 18721629 | N-terminal and/or C-terminal Cleaved Soluble PH20 Polypeptide and Use Thereof | SWIFT, CANDICE LEE | — |
| Art Unit | Apps |
|---|---|
| 1652 | 2 |
| 1657 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18940159 | METHOD FOR PRODUCING RECOMBINANT HYALURONIDASE | FRONDA, CHRISTIAN L | 1652 | §102§103§112DP | Non-Final OA | — | Pending | Nov 07, 2024 |
| 18940064 | METHOD FOR PRODUCING RECOMBINANT HYALURONIDASE | FRONDA, CHRISTIAN L | 1652 | §103DP | Non-Final OA | — | Pending | Nov 07, 2024 |
| 18721629 | N-terminal and/or C-terminal Cleaved Soluble PH20 Polypeptide and Use Thereof | SWIFT, CANDICE LEE | 1657 | §103§112 | Non-Final OA | — | Pending | Jun 18, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAlteogen Inc. has 3 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Christian L Fronda has the most, with 2 of Alteogen Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
